As president and chief executive officer of Delphinus Medical Technologies, Mark leads a team that has created an innovative whole breast ultrasound imaging device called SoftVue that is designed to find more cancer in dense breast screening than mammography alone through enhanced tissue characterization, leveraging streamlined workflow & unparalleled patient comfort with NO additional compression or radiation. Delphinus is a privately held medical technology company founded in 2010 and located in Novi, Michigan.
Mark has more than 35 years of experience leading innovative medical device companies to transform patient care and earn market leadership positions. Prior to joining Delphinus, Mark served as president and chief executive officer at OptiMedica Corp., a Silicon Valley based ophthalmic medical device company. He led the start-up venture through development and growth, completed multiple rounds of financing, and oversaw the company’s acquisition by Abbott Laboratories in 2013. He began his career in the medical technology industry as a sales representative at Grieshaber and Company, Inc., where he ultimately became vice president of U.S. sales and marketing and led the company through its acquisition by Alcon. During his tenure at Alcon, he led the retina business unit to substantial global share growth and advanced to vice president of vitreoretinal sales and global marketing.
Mark is a director on the Auburn University Foundation Board, serves on the Harbert College of Business Dean’s Advisory Council at Auburn University and is the creator of the idea behind the Harbert College of Business’s Tiger Cage, Top Tigers, and the Entrepreneurial Summit.
Mark has a bachelor’s degree in marketing from Auburn University and completed the Harvard Program for Management Development.
Dr. Duric, internationally acclaimed leader of innovative scientific research in the field of ultrasound imaging, is the Chief Technology Officer of Delphinus Medical Technologies. An expert in new imaging applications, he is Co-Inventor and developer of ultrasound tomography techniques that have led to the establishment of the Delphinus SoftVue™ imaging system. Dr. Duric is currently a professor and the Vice Chair of Research in the Department of Imaging Sciences at the University of Rochester. He was formerly the Professor of Oncology at Wayne State University and served as the Co-Leader of the Molecular Imaging Program at the Karmanos Cancer Institute. He has won a number of awards including Hero of Breast Cancer from Karmanos Cancer Institute, and he has been named Innovator of the Year by the State of Michigan and received a Distinguished Innovator Award from Wayne State University.
Shawn has served in successively responsible leadership positions throughout his career in finance and accounting. In his role as Chief Financial Officer at Delphinus, he oversees and directs all aspects of fiscal operations, and has piloted unparalleled levels of venture funding, well-distinguished in the medical device industry. His broad-based operational knowledge and experience have directed project management, clinical trial guidance, vendor contracts and partner relationships, while achieving on-time and under-budget successes through cost-sparing strategies and focused implementation. Prior to joining Delphinus, Shawn was head of finance at CytoPherx and Kux Architectural Products, and served as Controller at Advanced Material Process Corporation. Shawn received both his Bachelor of Arts in Accounting and Masters of Business Administration from the University of Michigan, Flint.
Dr. Littrup is a globally-recognized scientist in medical imaging and intervention. He is a board certified radiologist and clinically active breast imager who has conducted extensive research in the domains of cancer screening, ultrasound technology, biopsy guidance, and tumor ablation. As one of the original inventors of ultrasound tomography (UST) and Medical Advisor, he gives Delphinus Medical Technologies his unique full-spectrum experience from screening to biopsy and pioneering breast cryoablation. Dr. Littrup’s vision for the broad use of UST, from screening to treatment follow-up, thereby helped solidify the overall design and testing of the Delphinus SoftVue™ imaging system. He is an Interventional Radiologist at Crittenton Hospital Medical Center, Rochester, Michigan, recruited as Director of the Tumor Ablation Program, and assists in the development of the new breast center with guidance for new technology introduction. He is Professor of Radiology and Oncology at Wayne State University and was principal investigator of the Michigan Translational Research and Commercialization effort of the Michigan Economic Development Corporation. He held the position of full professor in the Department of Diagnostic Imaging at the Warren Alpert Medical School, Brown University, as well as Director of the Human Imaging Core and Ablation Program at Karmanos Cancer Institute. Dr. Littrup Is a graduate of the University of Michigan Medical School, completed a fellowship in prostatic ultrasound at St. Joseph Mercy Hospital in Ann Arbor, Michigan, and was a Radiology Society of North America Research Fellow developing tumor ablation technology and imaging.
Heather is an acknowledged clinical and regulatory professional with a highly successful record of first-ever accomplishments within the medical technology domain. During her nearly seven-year tenure at U-Systems. she was responsible for the development and implementation of a comprehensive global training program for the automated breast ultrasound product line, satisfying new FDA training mandates that became a model for the industry. She directed multiple prospective clinical trials in the U.S. and Europe, enrolling over 18,000 participants. This extraordinary effort and achievement culminated in the first-ever FDA approval for a breast ultrasound screening indication. Among her many firsts, she was instrumental in earning additional regulatory approvals in the U.S. and global markets. Heather has co-authored multiple publications and her research efforts have contributed to several published manuscripts in peer-reviewed journals.
Since he joined Delphinus as a founding member, Olivier Roy, PhD has held various leadership positions of increasing responsibility in the field of research and development. As the Vice President of Engineering, he leads all technical aspects of the SoftVue development and has been instrumental in converting fundamental research results into medical device innovations driving clinical success and company growth. His recognized broad-based scientific background, technical expertise, focused implementation, and leadership excellence have been key to achieve timely completion of mission critical deliverables, as well as to define and guide the company values and vision.
Prior to joining Delphinus, Dr. Roy was a post-doctoral fellow at the Karmanos Cancer Institute where he designed some of the foundational imaging techniques used in the SoftVue system. He received his Bachelor’s and Master’s Degrees in Communication Systems, and his PhD Degree in Signal Processing at the Swiss Federal Institute of Technology, Lausanne, Switzerland. Dr. Roy has published numerous peer-reviewed conference proceedings, journal papers, and book chapters in the area of signal processing, distributed source coding, beamforming, and ultrasound tomography. He holds several patents related to the SoftVue technology and other medical device innovations.